US equities
|
INTC
$64.58
▼-29.85%
AMZN
$238.70
▼-2.09%
NVDA
$203.81
▼-4.61%
MU
$878.93
▼-5.92%
SNDK
$1,155.51
▼-13.12%
GOOGL
$279.52
▼-1.51%
AMD
$500.49
▼-11.64%
SPCX
$137.72
▼-4.29%
INTC
$64.58
▼-29.85%
AMZN
$238.70
▼-2.09%
NVDA
$203.81
▼-4.61%
MU
$878.93
▼-5.92%
SNDK
$1,155.51
▼-13.12%
GOOGL
$279.52
▼-1.51%
AMD
$500.49
▼-11.64%
SPCX
$137.72
▼-4.29%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by Cadrenal Therapeutics
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
December 31, 2024
From
Cadrenal Therapeutics
Via
Business Wire
Tickers
CVKD
